Rhino-orbital mucormycosis after COVID-19 in the emergency department

Year 2022, Volume: 13 Issue: 3, 88 - 91, 30.09.2022

Burak Çelik , Halit Karakısa , Mehmet Kemal Emem , Bahadır Karaca

https://doi.org/10.33706/jemcr.1072718

Cited By: 1

Abstract

Introduction
Rhino-orbital mucormycosis (ROM) is an acute and fulminant infection. The number of ROM cases developing after coronavirus disease 2019 (COVID-19) is increasing.
Case Report
A 62-year-old male patient was admitted to the emergency department in northern Syria complaining of new-onset vision loss, swelling, and severe swelling of the left eye. It was noted that a 3-day course of prednisolone 250 mg was given to treat COVID-19. We found that he had a history of diabetes mellitus (DM) for 10 years. Physical examination revealed ptosis, proptosis, and ocular movement restriction in all directions in the left eye. All other systemic examinations were normal. A cranial and orbital magnetic resonance imaging scan performed after hospitalization for further evaluation and treatment showed an increase in the density of the sphenoid, ethmoid, and frontal sinus walls in the left orbit. Despite antifungal and surgical treatment, the patient died on day 14.
Conclusion
The use of steroids in treatment and the presence of concomitant DM are the main predisposing factors. The prognosis of this disease, which has a high mortality and morbidity, is adversely affected in geographic regions where health care is inadequate.

Keywords

COVID-19, emergency service, mucormycosis, rhino-orbital mucormycosis

References

• Gumral R., Yıldızoglu U., Saracli M. A., Kaptan K., Tosun F. & Yildiran S. T. (2011). A case of rhinoorbital mucormycosis in a leukemic patient with a literature review from Turkey. Mycopathologia, 172(5), 397.
• Oğuz H. & Yılmaz Ö. Increasing cases of Orbital Mucormycosis in recent years. Clinical and Experimental Ocular Trauma and Infection, 3(1), 10-11.
• Kaya O., Çavuş S. A., Turhan Ö., Taşbakan M. İ., Pullukçu H., Ertuğrul M. B. & et al. Evaluation of patients with zygomycosis. Turkish Journal of Medical Sciences, 44(3), 476-483..
• Cornely O. A., Alastruey-Izquierdo A., Arenz D., Chen S. C., Dannaoui E., Hochhegger B., & et al. Mucormycosis, E. C. M. M. (2019). Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medica, Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. The Lancet infectious diseases, 19(12), e405-e421.
• Aslan Ş., Omar Issa., Durak V. A., Çıkrıklar H. İ., & Özdemir F. (2020). Rhinocerebral Mucormycosis Case in the Emergency Room. Journal of Emergency Medicine Case Reports, 12(4), 106-107.
• Avatef Fazeli, M., Rezaei, L., Javadirad, E., Iranfar, K., Khosravi, A., Amini Saman, J., et al. (2021). Increased incidence of rhino‐orbital mucormycosis in an educational therapeutic hospital during the COVID‐19 pandemic in western Iran:, An observational study. Mycoses, 64(11), 1366-1377.
• Gangneux J. P., Bougnoux M. E., Dannaoui E., Cornet M., & Zahar J. R. (2020). Invasive fungal diseases during COVID-19: We should be prepared. Journal de mycologie medicale, 30(2), 100971.
• Rawson T. M., Moore L. S., Zhu N., Ranganathan N., Skolimowska K., Gilchrist, M., & et al (2020). Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing., Clinical Infectious Diseases, 71(9), 2459-2468.
• Ahmadika K et al. The double‐edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza‐associated mucormycosis versus COVID‐19 associated mucormycosis. Mycoses, 2021
• Uğurlu Ş. K., Selim S., Kopar A. & Songu M. (2015). Rhino-orbital mucormycosis: clinical findings and treatment outcomes of four cases. Turkish journal of ophthalmology, 45(4), 169.